Amneal Reports Third Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Amneal Pharmaceuticals (AMRX) Misses Q3 EPS by 5c; Offers FY22 Guidance
November 4, 2022 6:02 AM EDTAmneal Pharmaceuticals (: AMRX) reported Q3 EPS of $0.14, $0.05 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $546 million versus the consensus estimate of $564.24 million.
GUIDANCE:
Amneal Pharmaceuticals sees FY2022 EPS of $0.65-$0.70, versus the consensus of $0.68. Amneal... More
